Background: Bipolar disorder (BPD) is a chronic, episodic illness affecting nearly 50 million globally, with disability mostly due to depressive episodes (MDEs). Zuranolone is an investig...
Background: Zuranolone (SAGE-217) is an investigational, neuroactive steroid and GABAA receptor positive allosteric modulator evaluated in a Phase 3 trial in patients with PPD (NCT0297832...
Background: PPD is a common medical complication during and after pregnancy. Zuranolone (SAGE-217) is an investigational neuroactive steroid and GABAA receptor positive allosteric modulat...